Healthcare - Biotechnology - NASDAQ - US
$ 4.01
-2.67 %
$ 171 M
Market Cap
-7.86
P/E
CASH FLOW STATEMENT
-18.7 M
OPERATING CASH FLOW
-18.3 M
INVESTING CASH FLOW
36.8 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
DiaMedica Therapeutics Inc.
| Net Income | -19.4 M |
| Depreciation & Amortization | 30 K |
| Capital Expenditures | -24 K |
| Stock-Based Compensation | 1.68 M |
| Change in Working Capital | 93 K |
| Others | -1.25 M |
| Free Cash Flow | -18.8 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Dec-2011 | Dec-2010 | Dec-2009 | Dec-2008 | Dec-2007 | Dec-2006 | Dec-2005 | Dec-2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||||||||||||||
| Net Income | (19.4) | (13.7) | (13.6) | (12.3) | (10.6) | (5.7) | (4.3) | (2.2) | (1.4) | (4.8) | (7.4) | (10.1) | (6.6) | (4.3) | (2.4) | (1.9) | (2.3) | (0.8) | (0.2) | (0.6) |
| Depreciation & Amortization | 30 K | 25 K | 24 K | 21 K | 21 K | 15 K | 4 K | 2.2 K | 4.11 K | 2.47 K | 1.1 | 2.4 | 2.3 | 1.7 | 30.2 K | 26.7 K | 18.4 K | 3.32 K | 28.2 K | 6.41 K |
| Deferred Income Tax | 0 | 0 | 0.2 | 4 K | 74 K | 0 | 84.6 K | (0.2) | 21.5 K | (0.3) | (0.7) | (1.0) | 0 | (0.2) | (0.3) | (0.2) | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 1.7 | 1.5 | 1.6 | 1.8 | 1.2 | 0.6 | 0.4 | 0.3 | 0.1 | 0.3 | 0.7 | 1.0 | 0 | 0.3 | 0.3 | 0.2 | 0 | 0 | 0 | 0 |
| Other Operating Activities | (1.2) | 53 K | 58 K | 52 K | 49 K | 39 K | 93.6 K | 22.9 K | 21.5 K | 0.6 | 0.7 | 1.0 | 0.8 | 0.3 | 0.3 | 0.3 | 1.0 | 0 | 6.44 K | 34 K |
| Change in Working Capital | 93 K | 0.6 | (0.5) | 1.2 | 0.4 | (0.6) | 44 K | (0.9) | 53 K | 0.4 | 66.6 K | 1.2 | 36.2 K | (0.1) | 35.6 K | 41.7 K | 0.1 | 26.5 K | (0.7) | 0.5 |
| Cash From Operations | (18.7) | (11.5) | (12.3) | (9.2) | (9.1) | (5.7) | (3.9) | (3.0) | (1.4) | (3.8) | (5.5) | (5.5) | (3.4) | (2.4) | (2.1) | (1.5) | (1.2) | (0.8) | (0.8) | 99.4 K |
| INVESTING CASH FLOW | ||||||||||||||||||||
| Capital Expenditures | 24 K | 81 K | 22 K | 47 K | 2 K | 50 K | 22 K | 6.89 K | 5.39 K | 31.3 K | (0.1) | 63.4 K | 79.3 K | 57.8 K | 92.1 K | 85.3 K | (0.3) | (0.1) | 77 K | (0.1) |
| Other Items | (18.3) | 11.6 | (20.5) | (16.1) | (3.9) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 149 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | (18.3) | 11.5 | (20.5) | (16.1) | (3.9) | 50 K | 22 K | 6.89 K | 5.39 K | 31.3 K | (0.1) | 63.4 K | 79.3 K | 57.6 K | 92.1 K | 85.3 K | (0.3) | (0.1) | 77 K | (0.1) |
| FINANCING CASH FLOW | ||||||||||||||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 6 K | 6 K | 6 K | 5 K | 5 K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (0.2) | 0.1 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0.2 | 45 K | 75 K | 0.7 | 0.6 | 0.5 | 22.6 K | 0.2 | 95.4 K | 5.2 | 0.2 | 2.8 | 0 | 0 | 0 | 0 | 0.302 | 0 |
| Cash From Financing Activities | 36.8 | 6 K | 30.1 K | 28.8 | 70 K | 21.2 | 3.5 | 4.6 | 1.4 | 1.7 | 6.0 | 5.2 | 3.4 | 4.6 | 0 | 1.2 | 4.7 | 0.9 | 1.2 | 0.2 |
| CHANGE IN CASH | ||||||||||||||||||||
| Net Change In Cash | (0.2) | 21 K | (2.7) | 3.5 | (12.9) | 15.5 | (0.4) | 1.6 | 4.78 K | (2.1) | 0.3 | (0.4) | (0.1) | 2.2 | (2.2) | (0.4) | 3.2 | 4.17 K | 0.3 | 43.3 K |
| FREE CASH FLOW | ||||||||||||||||||||
| Free Cash Flow | (18.8) | (11.6) | (12.3) | (9.2) | (9.1) | (5.7) | (3.9) | (3.0) | (1.4) | (3.8) | (5.6) | (5.5) | (3.5) | (2.4) | (2.2) | (1.6) | (1.5) | (0.9) | (0.9) | (0.2) |